AI Software for X-Rays Gets FDA De Novo Classification for Bone Mineral Density Screening
Leveraging artificial intelligence, the Rho software assessment of X-rays may allow earlier detection of bone loss.
The Food and Drug Administration (FDA) has granted a De Novo classification to Rho™, an artificial intelligence (AI) software that may facilitate bone loss detection through opportunistic screening of X-rays for low bone mineral density (BMD).
Noting that less pronounced bone loss is more difficult for radiologists to assess via standard X-rays, 16 Bit, the manufacturer of the Rho software, said adjunctive use of Rho can be a viable alternative. Offering automated scans of a variety of X-rays, ranging from frontal chest projections and lumbar spine views to X-rays of the pelvis and knee, Rho provides alerts of possible low BMD, according to 16 Bit.
Rho™, an artificial intelligence (AI) software that may facilitate bone loss detection through opportunistic screening of X-rays for low bone mineral density (BMD), recently garnered a De Novo classification from the FDA. (Images courtesy of 16 Bit.)
In a recently published study in the Journal of the American College of Radiology (JACR), researchers found that Rho demonstrated area under the receiver operating characteristic (AUROC) curves of 89 percent, 87 percent and 82 percent in three independent data sets for detecting low BMD.
“An opportunistic screening tool such as this opens a window for early prevention and intervention strategies to slow the rate of bone loss,” noted lead study author Alexander Bilbily, M.D., FRCPC, the co-founder and co-CEO of 16 Bit, and an assistant professor and director of the Augmented Precision Medicine Lab at Sunnybrook Health Sciences Centre in Toronto, and colleagues.
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
